BioMed Research International

BioMed Research International / 2014 / Article
Special Issue

The Roads to Mitochondrial Dysfunction

View this Special Issue

Review Article | Open Access

Volume 2014 |Article ID 238463 |

Dimitry A. Chistiakov, Igor A. Sobenin, Victor V. Revin, Alexander N. Orekhov, Yuri V. Bobryshev, "Mitochondrial Aging and Age-Related Dysfunction of Mitochondria", BioMed Research International, vol. 2014, Article ID 238463, 7 pages, 2014.

Mitochondrial Aging and Age-Related Dysfunction of Mitochondria

Academic Editor: Ancha Baranova
Received16 Dec 2013
Accepted19 Mar 2014
Published10 Apr 2014


Age-related changes in mitochondria are associated with decline in mitochondrial function. With advanced age, mitochondrial DNA volume, integrity and functionality decrease due to accumulation of mutations and oxidative damage induced by reactive oxygen species (ROS). In aged subjects, mitochondria are characterized by impaired function such as lowered oxidative capacity, reduced oxidative phosphorylation, decreased ATP production, significant increase in ROS generation, and diminished antioxidant defense. Mitochondrial biogenesis declines with age due to alterations in mitochondrial dynamics and inhibition of mitophagy, an autophagy process that removes dysfunctional mitochondria. Age-dependent abnormalities in mitochondrial quality control further weaken and impair mitochondrial function. In aged tissues, enhanced mitochondria-mediated apoptosis contributes to an increase in the percentage of apoptotic cells. However, implementation of strategies such as caloric restriction and regular physical training may delay mitochondrial aging and attenuate the age-related phenotype in humans.

1. Introduction

Mitochondrial dysfunction, including decreased oxidative capacity and increased oxidative damage, is thought to substantially contribute to biological aging. A fundamental impact of mitochondria on aging has been suggested several decades ago. One concept considers aging as the result of an accumulation of damage to biomolecules due to the excessive production of highly toxic reactive oxygen species (ROS). This concept was developed as the mitochondrial theory of aging since mitochondria are the major producers of ROS in the cell [1]. According to this theory, with age, mitochondria accumulate ROS-induced damage and become dysfunctional. With time, the function of cells declines causing aging and subsequent death. This concept was supported by a growing body of experimental data from animal models. For example, mice developed to have high mutation rates in mitochondrial DNA (mtDNA) (so called mtDNA mutator mice) exhibited advanced aging phenotypes [2]. On the other hand, many recent studies have also provided data contradicting this theory. For example, the knockout of superoxide dismutase genes did not affect the lifespan of Caenorhabditis elegans [3]. Indeed, the role of mitochondria in aging seems to be very complex.

Mitochondria are subcellular self-autonomous organelles primarily responsible for the generation of energy and ATP synthesis. Besides this, mitochondria play an essential role in amino acid and lipid metabolism and regulation of apoptosis. Mitochondria have their own DNA; however, it encodes only 1% of the approximately 1,000 mitochondrial proteins. A vast majority of mitochondrial proteins are encoded by nuclear DNA and are transported to mitochondria from the cytoplasm. Mitochondria may change in their numbers and mass due to the dynamic processes such as fission and mitophagy. Mitophagy is a specific form of autophagy that is required to degrade dysfunctional or damaged mitochondria [4].

In this review, we briefly consider the major changes in the function and dynamics of mitochondria that make them dysfunctional and contribute to aging.

2. Changes in Mitochondrial DNA in Aging

The mitochondrial theory of aging is based on the fact that mitochondrial DNA (mtDNA) has a higher rate of mutation and less efficient repair machinery compared to nuclear DNA. The mutation rate of mtDNA is up to 15-fold higher than that of nuclear DNA [5]. Indeed, the accumulation of mutations in mtDNA may reach a critical threshold and cause adverse effects especially in mitochondria in which improperly functioning or damaged components of the respiratory chain need to be replaced. Mutations in mtDNA that alter the expression of oxidative phosphorylation (OxPhos) complexes can lead to mitochondrial dysfunction and accelerated ROS generation [6]. Development of the mtDNA mutator mouse, an animal with mutated mtDNA polymerase γ, highlighted the strong potential for mtDNA mutations in aging. These mice had a defective mechanism in their mtDNA proofreading during replication and resulted in the generation of a large number of new mutations and the development of premature aging phenotypes [2]. According to the “vicious cycle” concept, mtDNA mutations are accumulated exponentially and should be associated with marked burst in ROS production [7]. However, experiments involving mtDNA mutator mice have shown a linear progression in the accumulation of mtDNA mutations over the lifespan. There were no significant changes in ROS production and activity of antioxidant enzymes in the mtDNA mutator mice compared to the normal animals [8]. Indeed, these findings seriously compromise the “vicious cycle” theory that suggests that mtDNA mutations and impaired OxPhos but not ROS production are primarily responsible for premature aging in the mtDNA mutator mice.

In addition, due to the close proximity to the ROS-producing components of the respiratory chain and the absence of histones, mtDNA is highly prone to oxidative damage. In rat hepatocytes, the amount of 8-hydroxydeoxyguanosine, a marker of DNA oxidative damage, was 16 times higher in mtDNA than in the nuclear DNA [9]. In the skeletal muscles and liver of rats, substantial age-related reductions in mtDNA copy number were observed [10]. These findings suggest that the amount and integrity of mtDNA may decline with age and lead to aberrant expression of electron transport chain proteins, thereby impairing the mechanism of OxPhos [5].

3. Mitochondrial ROS Production and Aging

The electron transport chain located in the inner mitochondrial membrane consists of four protein complexes and is coupled with ATP synthase, an ATP-producing enzyme. ROS are considered to be unwanted and toxic by-products of the mitochondrial electron transport system.

Due to their extreme reactivity, ROS seem to be a major mediator of age-associated cellular damage. ROS can also act as signaling molecules [11]. Interestingly, low doses of ROS could actually promote longevity while high doses, in contrast, shorten the lifespan of C. elegans [12]. A paradoxical increase in longevity was observed in mitochondrial respiration mutants of C. elegans at elevated levels of ROS. ROS were shown to activate hypoxia-induced factor-1 (HIF-1), a transcription factor associated with prolonged lifespan [12]. Mild inhibition of mitochondrial respiration was shown to extend lifespan in many species such as C. elegans, Drosophila, and mice, suggesting that an increase in longevity by moderate suppression of mitochondrial respiration is evolutionarily preserved.

Antioxidant enzymes involved in ROS inactivation provide protection against oxidative stress. Indeed, defects in the activity of mitochondrial antioxidant enzymes may increase oxidative stress. Mice containing a transgene of a mitochondrial antioxidant enzyme such as Mn-dependent superoxide dismutase (Mn-SOD) or catalase showed increased longevity [13, 14] while mice lacking Mn-SOD died from premature death associated with severe mitochondrial dysfunction and neurodegeneration [15]. Mice deficient in p66shc, a protein involved in mitochondrial ROS production independent from OxPhos mechanism, displayed advanced resistance to oxidative stress and an increase in lifespan by 30% [16].

Enzymatic changes may affect mitochondrial oxidative capacity and ATP synthesis. In humans, ATP-producing capacity decreases by 8% per decade [5]. Similarly, elderly people were found to have a 1.5-fold reduction in oxidative capacity per mitochondrial volume and a 1.5-fold reduction per muscle volume [17]. Age-dependent decline in mitochondrial function may result from low physical activity because when physical activity is compared between old and young people, most studies failed to find any significant correlations between age, mitochondrial respiration, and ATP flux [18, 19].

4. Age-Dependent Changes in Mitochondrial Dynamics

The mitochondrial dynamics include the movement of mitochondria along the cytoskeleton, the regulation of mitochondrial architecture, and connectivity mediated by fusion/fission events [20]. This dynamic network is essential to maintain normal mitochondrial functions and participates in fundamental processes including aging. Mitochondrial biogenesis is the expansion of mitochondria through mechanisms involving growth (increase in mitochondrial mass) and division (increase of mitochondrial number).

With advanced age, the mitochondrial density in skeletal muscle was shown to decline gradually [21] and may suggest a decrease in mitochondrial biogenesis. The decline in mitochondrial biogenesis may result from an age-dependent reduction in levels of PGC-1α, a key regulator of biogenesis [22]. In aged mice, overexpression of PGC-1α in skeletal muscles was associated with reduced sarcopenia and an improvement of mitochondrial function [23].

Impaired balance between fission and fusion events may also be related to age-dependent decline in mitochondrial biogenesis. Fission is important for maintaining mitochondrial quality and integrity since it is involved in the selection of dysfunctional mitochondria. Defective mitochondria fail to function properly and have an impaired oxidative capacity skewed toward increased ROS production. These mitochondria are selectively removed by mitophagy, an autophagy-lysosome system that degrades dysfunctional mitochondria through fusion with lysosomes [4]. With age, mitophagy was observed to decline [24]. This decline is associated with an accumulation of damaged mitochondria, advanced oxidative stress, and increased apoptosis [25].

5. Mitochondrial Apoptotic Pathway and Aging

Mitochondria-mediated apoptosis is induced in response to proapoptotic stimuli or in the case of severe failure in OxPhos. Briefly, a caspase-dependent mechanism of mitochondrial apoptosis is accompanied by the release of cytochrome c and other factors from mitochondria, which then triggers the activation of a cascade of irreversible apoptotic events mediated by caspases. In the caspase-independent pathway, the release of endonuclease G and apoptosis-inducing factor (AIF) by mitochondria leads to the degradation of nuclear DNA [26].

Apoptosis was shown to increase significantly with age as reflected by an age-dependent gain in the percentage of apoptotic cells [27] and significant upregulation of caspase-independent proapoptotic pathway in aged rats [28] and elderly people [29]. Since no significant changes in the expression of caspases in older subjects were observed [29, 30], the caspase-dependent mechanism is unlikely to be activated with advanced age.

6. Genetic and Structural Alterations of Mitochondria in Atherogenesis

Increasing age is well known as an independent risk factor for the development of atherosclerosis [31, 32], and, therefore, according to a well-established point of view, atherosclerosis can be considered as a disease of aging [31, 32]. Premature or accelerated vascular aging and atherosclerosis can be associated with dysfunction of mitochondria [33, 34].

It is well known that in human pathology, a number of diseases are associated with somatic mutations in the mitochondrial genome (mtDNA) [35, 36]. Even though mitochondrial dysfunction leads to increased oxidative stress, the role of mitochondrial mutations in atherosclerosis has not received much attention so far [33, 34]. In a recent study we analyzed the association of mitochondrial genetic variation with the severity of carotid atherosclerosis (as assessed by carotid intima-media thickness (cIMT) and the presence of coronary heart disease (CHD)) and found that heteroplasmy for several mutations in the mtDNA in leukocytes, including C3256T, T3336C, G12315A, G13513A, G14459A, G14846A, and G15059A mutations, were significantly associated with both the severity of carotid atherosclerosis and the presence of CHD [37]. Electron-microscopic analysis of atherosclerotic lesions has also revealed a high variability in the ultrastructural appearance of mitochondria in human aortic atherosclerotic lesions compared with the appearance of mitochondria in the normal parts of the aortic intima (Figure 1) [38]. This prompted us to hypothesize that the structural variations in the appearance of mitochondria might reflect the existence of somatic mutations in the human mitochondrial genome which could be a determinant of the development of atherosclerotic lesions [38]. To test this hypothesis, we have compared the levels of heteroplasmy for several mitochondrial mutations previously proposed to be associated with different types of atherosclerotic lesions [38]. The homogenates of unaffected aortic intimae and lipofibrous plaques of human aortas were compared to reveal the average level of heteroplasmy for A1555G, C3256T, T3336T, G12315A, G14459A, and G15059A mutations of human mitochondrial genome [38]. It has been found that at least four mutations of mitochondrial genome, namely, A1555G in MT-RNR1 gene, C3256T in MT-TL1 gene, G12315A in MT-TL2 gene, and G15059A in MT-CYB gene, have significantly higher prevalence and mean value in lipofibrous plaques as compared to nonatherosclerotic intima [38]. The findings that somatic mutations in the mitochondrial genome are associated with the development of atherosclerosis [37, 38] should encourage further exploration of the concept that mitochondrial DNA heteroplasmy might be used as a biomarker of atherogenesis.

7. Mitochondrial Quality Control and Aging

Mitochondria have a number of specific enzymes such as chaperones, proteases, and methionine reductase to refold and eliminate misfolded proteins [39]. In the short-lived fungus Podospora anserina, deletion of mitochondrial protease PaLon1 involved in protein quality control leads to significantly shortened lifespan while overexpression of PaLon1 did not affect fungus longevity but was associated with prolonged good health and improved mitochondrial function [40]. The mitochondrial protease Lon is responsible for degradation of oxidized proteins and its downregulation is suggested to contribute to aging and age-related diseases [41]. Thus, the proper function of the mitochondria-associated quality control system may be associated with longevity or at least extend the healthy lifespan.

Mitochondria contribute to the cellular system of the protein quality control associated with ubiquitination and protease-dependent degradation of unfolded proteins by degrading cytosolic proteins located at the outer mitochondrial membrane [42]. Generally, the ubiquitin-protease system activity was shown to decline with age in mammals [43]. However, expression of some components of this system such as ubiquitin-specific proteases and certain proteasome subunits is upregulated with aging while levels of other components remain unchanged or decrease [44]. In muscles of aged rats, the expression of proteasome-associated proteins was increased and levels of 26S proteasomes were found to be higher by 2- to 3-fold of those of adult animals. Indeed, age-dependent activation of the ubiquitin-protease system may contribute to enhanced degradation of myofibrillar proteins and age-related muscle atrophy. The specific role of mitochondrial-associated protein degradation in aging is not completely understood and needs to be characterized.

8. Conclusion

It is clear that a role of mitochondria in aging is more complicated than suggested by the mitochondrial theory of aging. Multiple changes in mitochondrial function, structure, distribution, and dynamics contribute to aging or age-related features. Studies in model organisms such as yeast, C. elegans, Drosophila, and mice have shown that both suppression and stimulation of mitochondrial function can extend lifespan. For example, downregulation of mTOR signaling associated with enhanced protein synthesis and cell growth was shown to increase longevity in model organisms through improved mitochondrial efficiency and better energy consumption [45]. Figure 2 outlines the consequence of the mechanisms/factors by which caloric restriction may improve mitochondrial function, delay mitochondrial aging, and expand longevity.

As a consequence, caloric restriction (CR) that usually involves consuming 20–40% lower calories than normal was suggested as a promising intervention to increase both median and maximal lifespan in humans [46]. In a CR trial CALERIE based on 25% CR, CR patients were shown to have less mtDNA damage, more mtDNA content, and increased expression of some antioxidant enzymes, therefore suggesting that CR improves mitochondrial function and delays mitochondrial aging through reducing oxidative stress. The increase in expression of several proteins involved in mitochondrial biogenesis such as PGC-1α, Tfam, and SIRT1 was reported in CR patients compared to controls [47]. In summary, CR reduces oxidative stress and enhances mitochondrial biogenesis in order to produce mitochondria that are more efficient in ATP production, have optimal oxidative capacity, and generate less ROS.

Exercise training alone or in combination with CR may also represent an efficient strategy to delay mitochondrial aging and age-related dysfunction in humans through mechanisms stimulating mitochondrial biogenesis and oxidative capacity and improving protein quality control [48]. There is strong evidence that exercise training can optimize mitochondrial function in elderly individuals [49, 50]. Exercise, combined with a low carbohydrate (glycogen) diet, was shown to increase the expression of PGC-1α and optimize the oxidative capacity of human skeletal muscle [51]. In the CALERIE trial, combining CR with exercise training resulted in a 38% reduction in the estimated risk of cardiovascular disease, an important age-associated pathology, compared to controls [52]. Indeed, increased physical activity or even simply adopting active style habits may clearly reduce the rate of mitochondrial decline and attenuate the age-related phenotype.

Conflict of Interests

The authors report no conflict of interests regarding the publication of this paper.


The authors wish to thank the Ministry of Education and Science of the Russian Federation and the School of Medical Sciences, University of New South Wales, Sydney, for the support of their work.


  1. D. Harman, “The biologic clock: the mitochondria?” Journal of the American Geriatrics Society, vol. 20, no. 4, pp. 145–147, 1972. View at: Google Scholar
  2. D. Edgar and A. Trifunovic, “The mtDNA mutator mouse: dissecting mitochondrial involvement in aging,” Aging, vol. 1, no. 12, pp. 1028–1032, 2009. View at: Google Scholar
  3. R. Doonan, J. J. McElwee, F. Matthijssens et al., “Against the oxidative damage theory of aging: superoxide dismutases protect against oxidative stress but have little or no effect on life span in Caenorhabditis elegans,” Genes and Development, vol. 22, no. 23, pp. 3236–3241, 2008. View at: Publisher Site | Google Scholar
  4. W. X. Ding and X. M. Yin, “Mitophagy: mechanisms, pathophysiological roles, and analysis,” Biol Chem, vol. 393, pp. 547–564, 2012. View at: Google Scholar
  5. K. R. Short, M. L. Bigelow, J. Kahl et al., “Decline in skeletal muscle mitochondrial function with aging in humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 15, pp. 5618–5623, 2005. View at: Publisher Site | Google Scholar
  6. D. C. Wallace, “Mitochondrial DNA mutations in disease and aging,” Environmental and Molecular Mutagenesis, vol. 51, no. 5, pp. 440–450, 2010. View at: Publisher Site | Google Scholar
  7. M. F. Alexeyev, S. P. LeDoux, and G. L. Wilson, “Mitochondrial DNA and aging,” Clinical Science, vol. 107, no. 4, pp. 355–364, 2004. View at: Publisher Site | Google Scholar
  8. A. Trifunovic, A. Hansson, A. Wredenberg et al., “Somatic mtDNA mutations cause aging phenotypes without affecting reactive oxygen species production,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 50, pp. 17993–17998, 2005. View at: Publisher Site | Google Scholar
  9. C. Richter, J.-W. Park, and B. N. Ames, “Normal oxidative damage to mitochondrial and nuclear DNA is extensive,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 17, pp. 6465–6467, 1988. View at: Google Scholar
  10. R. Barazzoni, K. R. Short, and K. S. Nair, “Effects of aging on mitochondrial DNA copy number and cytochrome c oxidase gene expression in rat skeletal muscle, liver, and heart,” Journal of Biological Chemistry, vol. 275, no. 5, pp. 3343–3347, 2000. View at: Publisher Site | Google Scholar
  11. W. Yang and S. Hekimi, “A mitochondrial superoxide signal triggers increased longevity in caenorhabditis elegans,” PLoS Biology, vol. 8, no. 12, Article ID e1000556, 2010. View at: Publisher Site | Google Scholar
  12. S.-J. Lee, A. B. Hwang, and C. Kenyon, “Inhibition of respiration extends C. elegans life span via reactive oxygen species that increase HIF-1 activity,” Current Biology, vol. 20, no. 23, pp. 2131–2136, 2010. View at: Publisher Site | Google Scholar
  13. J. Sun, D. Folk, T. J. Bradley, and J. Tower, “Induced overexpression of mitochondrial Mn-superoxide dismutase extends the life span of adult Drosophila melanogaster,” Genetics, vol. 161, no. 2, pp. 661–672, 2002. View at: Google Scholar
  14. S. E. Schriner, N. J. Linford, G. M. Martin et al., “Medecine: extension of murine life span by overexpression of catalase targeted to mitochondria,” Science, vol. 308, no. 5730, pp. 1909–1911, 2005. View at: Publisher Site | Google Scholar
  15. R. M. Lebovitz, H. Zhang, H. Vogel et al., “Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 18, pp. 9782–9787, 1996. View at: Publisher Site | Google Scholar
  16. E. Migliaccio, M. Giorgio, and P. G. Pelicci, “Apoptosis and aging: role of p66Shc redox protein,” Antioxidants and Redox Signaling, vol. 8, no. 3-4, pp. 600–608, 2006. View at: Publisher Site | Google Scholar
  17. K. E. Conley, S. A. Jubrias, and P. C. Esselman, “Oxidative capacity and ageing in human muscle,” Journal of Physiology, vol. 526, no. 1, pp. 203–210, 2000. View at: Google Scholar
  18. E. J. Brierley, M. A. Johnson, A. Bowman et al., “Mitochondrial function in muscle from elderly athletes,” Annals of Neurology, vol. 41, no. 1, pp. 114–116, 1997. View at: Publisher Site | Google Scholar
  19. R. G. Larsen, D. M. Callahan, S. A. Foulis, and J. A. Kent-Braun, “Age-related changes in oxidative capacity differ between locomotory muscles and are associated with physical activity behavior,” Applied Physiology, Nutrition and Metabolism, vol. 37, no. 1, pp. 88–99, 2012. View at: Publisher Site | Google Scholar
  20. C. S. Palmer, L. D. Osellame, D. Stojanovski, and M. T. Ryan, “The regulation of mitochondrial morphology: intricate mechanisms and dynamic machinery,” Cellular Signalling, vol. 23, no. 10, pp. 1534–1545, 2011. View at: Publisher Site | Google Scholar
  21. J. D. Crane, M. C. Devries, A. Safdar, M. J. Hamadeh, and M. A. Tarnopolsky, “The effect of aging on human skeletal muscle mitochondrial and intramyocellular lipid ultrastructure,” The Journals of Gerontology Series A, vol. 65, no. 2, pp. 119–128, 2010. View at: Publisher Site | Google Scholar
  22. T. Wenz, S. G. Rossi, R. L. Rotundo, B. M. Spiegelman, and C. T. Moraes, “Increased muscle PGC-1α expression protects from sarcopenia and metabolic disease during aging,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 48, pp. 20405–20410, 2009. View at: Publisher Site | Google Scholar
  23. T. Wenz, “Mitochondria and PGC-1α in aging and age-associated diseases,” Journal of Aging Research, vol. 2011, Article ID 810619, 12 pages, 2011. View at: Publisher Site | Google Scholar
  24. G. Cavallini, A. Donati, M. Taddei, and E. Bergamini, “Evidence for selective mitochondrial autophagy and failure in aging,” Autophagy, vol. 3, no. 1, pp. 26–27, 2007. View at: Google Scholar
  25. E. Masiero and M. Sandri, “Autophagy inhibition induces atrophy and myopathy in adult skeletal muscles,” Autophagy, vol. 6, no. 2, pp. 307–309, 2010. View at: Publisher Site | Google Scholar
  26. S.-Y. Jeong and D.-W. Seol, “The role of mitochondria in apoptosis,” Journal of Biochemistry and Molecular Biology, vol. 41, no. 1, pp. 11–22, 2008. View at: Google Scholar
  27. E. Marzetti and C. Leeuwenburgh, “Skeletal muscle apoptosis, sarcopenia and frailty at old age,” Experimental Gerontology, vol. 41, no. 12, pp. 1234–1238, 2006. View at: Publisher Site | Google Scholar
  28. C. Leeuwenburgh, C. M. Gurley, B. A. Strotman, and E. E. Dupont-Versteegden, “Age-related differences in apoptosis with disuse atrophy in soleus muscle,” American Journal of Physiology, vol. 288, no. 5, pp. R1288–R1296, 2005. View at: Publisher Site | Google Scholar
  29. S. Y. Park, H. Y. Kim, J. H. Lee, K. H. Yoon, M. S. Chang, and S. K. Park, “The age-dependent induction of apoptosis-inducing factor (AIF) in the human semitendinosus skeletal muscle,” Cellular and Molecular Biology Letters, vol. 15, no. 1, pp. 1–12, 2010. View at: Publisher Site | Google Scholar
  30. S. A. Whitman, M. J. Wacker, S. R. Richmond, and M. P. Godard, “Contributions of the ubiquitin-proteasome pathway and apoptosis to human skeletal muscle wasting with age,” Pflugers Archiv European Journal of Physiology, vol. 450, no. 6, pp. 437–446, 2005. View at: Publisher Site | Google Scholar
  31. E. Bolton and C. Rajkumar, “The ageing cardiovascular system,” Reviews in Clinical Gerontology, vol. 21, no. 2, pp. 99–109, 2011. View at: Publisher Site | Google Scholar
  32. J. C. Wang and M. Bennett, “Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence,” Circulation Research, vol. 111, pp. 245–259, 2012. View at: Google Scholar
  33. D. A. Chistiakov, I. A. Sobenin, Y. V. Bobryshev, and A. N. Orekhov, “Mitochondrial dysfunction and mitochondrial DNA mutations in atherosclerotic complications in diabetes,” World Journal of Cardiology, vol. 4, pp. 148–156, 2012. View at: Google Scholar
  34. I. A. Sobenin, D. A. Chistiakov, Y. V. Bobryshev, A. Y. Postnov, and A. N. Orekhov, “Mitochondrial mutations in atherosclerosis: new solutions in research and possible clinical applications,” Current Pharmaceutical Design, vol. 19, pp. 5942–5953, 2013. View at: Google Scholar
  35. W. J. Craigen, “Mitochondrial DNA mutations: an overview of clinical and molecular aspects,” Methods in Molecular Biology, vol. 837, pp. 3–15, 2012. View at: Publisher Site | Google Scholar
  36. T. J. Nicholls, J. Rorbach, and M. Minczuk, “Mitochondria: mitochondrial RNA metabolism and human disease,” The International Journal of Biochemistry & Cell Biology, vol. 45, pp. 845–849, 2013. View at: Google Scholar
  37. I. A. Sobenin, M. A. Sazonova, A. Y. Postnov, J. T. Salonen, Y. V. Bobryshev, and A. N. Orekhov, “Association of mitochondrial genetic variation with carotid atherosclerosis,” PLoS ONE, vol. 8, Article ID e68070, 2013. View at: Google Scholar
  38. I. A. Sobenin, M. A. Sazonova, A. Y. Postnov, Y. V. Bobryshev, and A. N. Orekhov, “Changes of mitochondria in atherosclerosis: possible determinant in the pathogenesis of the disease,” Atherosclerosis, vol. 227, pp. 283–288, 2013. View at: Google Scholar
  39. H. D. Osiewacz and D. Bernhardt, “Mitochondrial quality control: impact on aging and life span—a mini-review,” Gerontology, vol. 59, pp. 413–420, 2013. View at: Google Scholar
  40. C. Adam, M. Picard, M. Dequard-Chablat, C. H. Sellem, S. H. Denmat, and V. Contamine, “Biological roles of the Podospora anserina mitochondrial Lon protease and the importance of its N-domain,” PLoS ONE, vol. 7, Article ID e38138, 2012. View at: Google Scholar
  41. J. K. Ngo, L. C. D. Pomatto, and K. J. A. Davies :, “Upregulation of the mitochondrial Lon Protease allows adaptation to acute oxidative stress but dysregulation is associated with chronic stress, disease, and aging,” Redox Biology, vol. 1, pp. 258–264, 2013. View at: Google Scholar
  42. E. B. Taylor and J. Rutter, “Mitochondrial quality control by the ubiquitin-proteasome system,” Biochemical Society Transactions, vol. 39, no. 5, pp. 1509–1513, 2011. View at: Publisher Site | Google Scholar
  43. P. Löw, “The role of ubiquitin-proteasome system in ageing,” General and Comparative Endocrinology, vol. 172, no. 1, pp. 39–43, 2011. View at: Publisher Site | Google Scholar
  44. M. Altun, H. C. Besche, H. S. Overkleeft et al., “Muscle wasting in aged, sarcopenic rats is associated with enhanced activity of the ubiquitin proteasome pathway,” Journal of Biological Chemistry, vol. 285, no. 51, pp. 39597–39608, 2010. View at: Publisher Site | Google Scholar
  45. Y. Pan, Y. Nishida, M. Wang, and E. Verdin, “Metabolic regulation, mitochondria and the life-prolonging effect of rapamycin: a mini-review,” Gerontology, vol. 58, pp. 524–530, 2012. View at: Google Scholar
  46. C. M. Peterson, D. L. Johannsen, and E. Ravussin, “Skeletal muscle mitochondria and aging: a review,” Journal of Aging Research, vol. 2012, Article ID 194821, 20 pages, 2012. View at: Publisher Site | Google Scholar
  47. A. E. Civitarese, S. Carling, L. K. Heilbronn et al., “Calorie restriction increases muscle mitochondrial biogenesis in healthy humans,” PLoS Medicine, vol. 4, no. 3, pp. 485–494, 2007. View at: Publisher Site | Google Scholar
  48. J. L. Steiner, E. A. Murphy, J. L. McClellan, M. D. Carmichael, and J. M. Davis, “Exercise training increases mitochondrial biogenesis in the brain,” Journal of Applied Physiology, vol. 111, no. 4, pp. 1066–1071, 2011. View at: Publisher Site | Google Scholar
  49. K. R. Short, J. L. Vittone, M. L. Bigelow et al., “Impact of aerobic exercise training on age-related changes in insulin sensitivity and muscle oxidative capacity,” Diabetes, vol. 52, no. 8, pp. 1888–1896, 2003. View at: Publisher Site | Google Scholar
  50. S. Ghosh, R. Lertwattanarak, N. Lefort et al., “Reduction in reactive oxygen species production by mitochondria from elderly subjects with normal and impaired glucose tolerance,” Diabetes, vol. 60, no. 8, pp. 2051–2060, 2011. View at: Publisher Site | Google Scholar
  51. N. Psilander, P. Frank, M. Flockhart, and K. Sahlin, “Exercise with low glycogen increases PGC-1α gene expression in human skeletal muscle,” European Journal of Applied Physiology, vol. 113, pp. 951–963, 2013. View at: Google Scholar
  52. M. Lefevre, L. M. Redman, L. K. Heilbronn et al., “Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals,” Atherosclerosis, vol. 203, no. 1, pp. 206–213, 2009. View at: Publisher Site | Google Scholar

Copyright © 2014 Dimitry A. Chistiakov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.